The latest coronavirus developments and scientific research on prevention and treatment.
Though the U.S. population is aging, nursing home capacity has declined nationwide since the COVID-19 pandemic began. According to a study published in JAMA Internal Medicine this week, one quarter… read more.
Most COVID-19 vaccine hesitancy is rooted in concerns that can be addressed and effectively reduced over time, according to a new study following more than 1.1 million people… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
The electronic health record data analysed in this study is anonymised and never leaves a secure data environment, which is only accessible by approved researchers working on approved… read more.
A new study from Karolinska Institutet in Sweden shows that an unusual heart rhythm disorder, POTS, is particularly common in people with long COVID. The majority of those… read more.
Children and adolescents are at a significantly higher risk of various SARS-CoV-2 infection (PASC/long COVID) outcomes after reinfection with SARS-CoV-2, researchers reported in Lancet Infectious Diseases on September… read more.
A widely available and affordable drug has been shown to be effective in treating seriously ill COVID-19 patients, according to a new international study led by researchers at… read more.
Millions of people around the world are suffering with the serious cardiovascular effects of Covid infection and long Covid. A lack of clear guidance on how to reduce… read more.
Novavax Inc. announced a milestone payment from Takeda has been triggered by regulatory approval in Japan for Novavax’s Covid-19 vaccine Nuvaxovid 2025-2026 Formula (Intramuscular Injection 1 mL) formulated… read more.
In an analysis by race, sex, age, and geography, alcohol-induced death rates in 2024 are nearly double those in 1999, with a sharp increase at the onset of the… read more.
Moderna Inc. announced that the FDA has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2… read more.
Novavax, Inc. announced that the FDA has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19 in individuals 65 years of age and older, or 12 years… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
